Coya Therapeutics Reports $3.6 Million Collaboration Revenue in Q3 2025

Coya Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a collaboration revenue of $3.6 million, a significant increase from zero revenue in the same period last year. For the nine months ending September 30, 2025, total collaboration revenue reached $4.0 million, compared to $3.6 million for the same period in 2024. The revenue growth is attributed to the recognition of $3.3 million in license revenue following the FDA's acceptance of the Investigational New Drug (IND) application for its lead product, COYA 302, aimed at treating amyotrophic lateral sclerosis (ALS).

Operating expenses for the third quarter totaled $6.0 million, up from $4.5 million in the prior year, driven primarily by increased research and development costs, which rose to $2.9 million from $2.2 million. The increase in R&D expenses reflects the advancement of COYA 302 into clinical trials, with a notable shift in expense categorization as costs associated with COYA 302 were reclassified from preclinical to clinical product candidate expenses. General and administrative expenses also increased to $2.6 million, up from $2.2 million, largely due to higher employee compensation and public filing costs.

Coya's net loss for the third quarter was $2.1 million, a reduction from a net loss of $4.0 million in the same quarter of 2024. For the nine-month period, the net loss was $15.5 million, compared to $12.0 million in the previous year. The company reported an accumulated deficit of $56.3 million as of September 30, 2025. The increase in net loss is attributed to higher operating expenses, particularly in R&D, as the company continues to invest in its product development pipeline.

In terms of operational developments, Coya Therapeutics is actively conducting the ALSTARS Trial, a Phase 2 study for COYA 302, which is designed to evaluate the safety and efficacy of the treatment for ALS. The company has also expanded its workforce, with a total employee count that reflects its ongoing commitment to advancing its clinical programs. As of September 30, 2025, Coya had $28.1 million in cash and cash equivalents, bolstered by a recent public offering that raised approximately $23.0 million, expected to fund operations for at least the next year.

Looking ahead, Coya Therapeutics anticipates continued significant expenses as it advances its clinical trials and seeks regulatory approvals for its product candidates. The company emphasizes the need for additional financing to support its growth strategy, which may include equity offerings, collaborations, and other capital sources. The management remains optimistic about the potential of its therapies targeting regulatory T cells, which are believed to play a crucial role in treating various diseases, including neurodegenerative conditions.